Skip to main content
Article thumbnail
Location of Repository

Elderly patients with stage III or IV ovarian cancer : should they receive standard care?

By Monika Janda, Danny R. Youlden, Peter D. Baade, Dan Jackson and Andreas Obermair

Abstract

Due to the higher risk of morbidity and perioperative mortality compared to younger patients, elderly patients with advanced ovarian cancer are challenging to treat. A population-based analysis was performed to predict treatment outcomes and establish risk factors for early death of elderly patients with advanced ovarian cancer using a cohort of 3994 women diagnosed with stage III or IV ovarian cancer between 1992 and 1999, registered with the Surveillance, Epidemiology and End Results Cancer Registries. A multivariate accelerated failure time model allowed estimation of a risk factor model for overall survival. Patient's age, stage at presentation, presence of comorbidities, and oncology treatment facility were independently associated with overall survival at 12 months from diagnosis. Patients were assigned to low (0–7 points), moderate (8–14 points) or high (≥15 points) risk groups according to accumulation of risk factors, which showed good ability to predict 12-month mortality (receiver–operator characteristics curve [ROC] derivation cohort = 0.763; ROC validation cohort = 0.756). Across all three risk groups, patients who received both surgery and chemotherapy showed significantly improved survival as compared to patients who received only surgery or chemotherapy. For patients 80 years and over who had upfront surgery, perioperative mortality was significantly greater in the high-risk group (21%; 95% CI = 16–26%) compared to patients within the moderate (8%; 95% CI = 5–12%) and low-risk groups (0%; 95% CI = 0–11%). The risk factor profile established could be helpful to plan future clinical trials to establish optimal treatment for elderly patients with advanced stage ovarian cancer

Topics: 111716 Preventive Medicine, 111712 Health Promotion, 111799 Public Health and Health Services not elsewhere classified, elderly patients, outcome, ovarian cancer, survival, treatment
Publisher: Blackwell Publishing
Year: 2008
DOI identifier: 10.1111/j.1525-1438.2007.01122.x
OAI identifier: oai:eprints.qut.edu.au:14847

Suggested articles

Citations

  1. (2007). A wide difference in cancer survival between middle aged and elderly patients in Europe.
  2. (2004). An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol
  3. (2002). Assessing comorbidity using claims data: an overview. Med Care
  4. (2006). Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection.
  5. (2000). Attitudes to radical gynecological oncology surgery in the elderly: a pilot study.
  6. (1996). Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol
  7. (2005). Cancer in the older person. Cancer Treat Rev
  8. (2007). Cancer Network, Senior Adult Oncology, Available from: http://www.nccn.org/professionals/physician_gls/PDF/senior.pdf. accessed 7
  9. (2001). Cancer screening in elderly patients: a framework for individualized decision making. Jama
  10. (2006). Cancer statistics,
  11. (2000). Development of a comorbidity index using physician claims data.
  12. (2001). Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol Oncol
  13. (2001). Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA
  14. (2006). Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients.
  15. (2004). Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol
  16. (2007). Health and Human Services, Administration of Aging. Statistics on the Aging Population. Available from http://www.aoa.gov/prof/Statistics/statistics.asp, accessed 7
  17. (2007). Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis.
  18. (2002). Measuring complications of cancer treatment using the SEER-Medicare data. Med Care
  19. (1994). Myths and biases related to cancer in the elderly. Cancer
  20. (2005). Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol
  21. (2007). Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients.
  22. (1993). Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer
  23. (2002). Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care
  24. (2007). Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer
  25. (2004). Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer.
  26. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.
  27. (2007). SEER Stage Distribution by Race and Age Group For Ovary Cancer, Females SEER 9 Registries for 1995-2001 Available from: http://canques.seer.cancer.gov/ accessed 7
  28. (2006). Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer
  29. (1993). Survival and treatment differences by age. Cancer
  30. (2007). The EORTC Gynaecological Cancer Group. EORTC 55971: A randomised phase III study comparing upfront debulking surgery vs. neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma.
  31. (1993). The risk of determining risk with multivariable models. Ann Intern Med
  32. (2006). Transcending the volume-outcome relationship in cancer care.
  33. (2003). Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States.
  34. (2002). Use of SEERMedicare data for measuring cancer surgery. Med Care
  35. (2002). Utility of the SEER-Medicare data to identify chemotherapy use. Med Care
  36. (2002). Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.